Friedman Billings Downgrades Progenics Pharma (PGNX) to Underperform
More News related to PGNX
- Progenics Announces Wyeth Has Received RELISTOR Approval in Australia
- Progenics Reports Third Quarter 2008 Financial Results and Corporate Updates
- Progenics Selects Small-Molecule Hepatitis C Drug Candidate for Clinical Development
- Progenics (PGNX) Reports Positive Interim Phase 2 Results for Novel HIV Therapy PRO 140
- Progenics Reports Positive Interim Phase 2 Results for Two Dosage Forms of Novel HIV Therapy PRO 140
More News related to Downgrades
- Citi Initiates Coverage on US Soft Drink Makers
- William Blair Initiates Coverage on Data Networking Stocks
- Caris Starts Coverage on Ariba (ARBA), Concur (CNQR), salesforce.com (CRM), Taleo (TLEO)
- Oppenheimer Initiates Coverage on ViroPharma (VPHM)
- Oppenheimer Initiates Coverage on Cadence Pharmaceuticals (CADX) with an Outperform
Friedman Billings downgrades Progenics Pharmaceuticals (Nasdaq: PGNX) from Market Perform to Underperform with a $12 price target.
Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat debilitating conditions and life-threatening diseases in the United States and internationally.
Related Categories
DowngradesStocks Mentioned
+0.48Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
